ATRA Atara Biotherapeutics Inc

Price (delayed)

$8.51

Market cap

$85.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.28

Enterprise value

$132.52M

?
Relative Growth: Rel. Growth: 8
Relative Strength: Rel. Strength: 32
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 18

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. ...

Highlights
The debt has decreased by 10% YoY
Atara Biotherapeutics's gross margin has increased by 13% YoY but it has decreased by 4.9% QoQ
Atara Biotherapeutics's revenue has shrunk by 97% YoY and by 73% QoQ
The gross profit has plunged by 96% YoY and by 75% from the previous quarter

Key stats

What are the main financial stats of ATRA

ATRA stock price

How has the Atara Biotherapeutics stock price performed over time
Intraday
-7.75%
1 week
3.15%
1 month
-1.85%
1 year
-29.84%
YTD
-52.96%
QTD
-25.87%

Financial performance

How have Atara Biotherapeutics's revenue and profit performed over time
Revenue
$6.19M
Gross profit
$5.66M
Operating income
-$14.23M
Net income
-$16.69M
Gross margin
91.4%
Net margin
-269.4%
The operating income has plunged by 125% from the previous quarter
Atara Biotherapeutics's revenue has shrunk by 97% YoY and by 73% QoQ
The gross profit has plunged by 96% YoY and by 75% from the previous quarter
The net income has plunged by 76% from the previous quarter

Price vs fundamentals

How does ATRA's price correlate with its fundamentals

Growth

What is Atara Biotherapeutics's growth rate over time

Valuation

What is Atara Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
20.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.39
The EPS has plunged by 68% from the previous quarter
The equity has declined by 6% year-on-year
ATRA's P/S is 143% above its last 4 quarters average of 8.5 and 10% above its 5-year quarterly average of 18.7
Atara Biotherapeutics's revenue has shrunk by 97% YoY and by 73% QoQ

Efficiency

How efficient is Atara Biotherapeutics business performance
Atara Biotherapeutics's return on invested capital has shrunk by 196% YoY and by 136% QoQ
The company's return on assets has shrunk by 107% QoQ

Dividends

What is ATRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATRA.

Financial health

How did Atara Biotherapeutics financials performed over time
The total assets is 64% less than the total liabilities
The total assets has contracted by 43% YoY but it has grown by 5% from the previous quarter
ATRA's total liabilities is down by 19% year-on-year
ATRA's debt to equity is up by 14% year-on-year
The debt has decreased by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.